Leigh Zawel - Sep 7, 2021 Form 4 Insider Report for Cullinan Oncology, Inc. (CGEM)

Role
Chief Scientific Officer, Small Molecules
Signature
/s/ Jeffrey Trigilio, Attorney-in-Fact
Stock symbol
CGEM
Transactions as of
Sep 7, 2021
Transactions value $
-$814,016
Form type
4
Date filed
9/8/2021, 04:15 PM
Previous filing
Aug 26, 2021
Next filing
Sep 21, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CGEM Common Stock Sale -$814K -28.1K -30.07% $28.95 65.4K Sep 7, 2021 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on April 26, 2021.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.62 to $29.29. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Remarks:

Chief Scientific Officer, Small Molecules